TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06687382: A Phase IIa Randomized, Controlled, Open-label Clinical Trial to Assess the Efficacy, Safety, and Tolerability of the Investigational Medicinal Product MBK-01, FSPIM (Full Spectrum & Purified Intestinal Microbiota) Oral

Sponsor: Mikrobiomik Healthcare Company S.L. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 81 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06687382 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06687382 Rescue Dossier →